Unlock News Summary by Subscribing to iPick.ai Premium!
Ask anything related to CUE. [ FAQ on what and how to ask] For non-CUE questions, click the logo in the upper-right corner to return to the main page and ask there.
Unlock YouTube Video by Subscribing to iPick.ai Premium!
Not available
Address: 40 Guest Street, Boston, MA, United States, 02135
Employees: 29
Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company's lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inflammation and drive Treg-mediated tolerance. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
Principal Accounting Officer & Chief Business Officer
Senior Vice President of Intellectual Property
President, CEO & Director
Co-Founder
Co-Founder
Co-Founder and Chairman of Scientific & Clinical Advisory Board
Chief Financial Officer
Chief Officer of Public & Investor Relations
Chief Legal & Compliance Officer and Corporate Secretary
Interim Chief Development Officer
My Watchlist
